stockrow
Friday 6 November 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
5.18
0.09
−1.71%
Follow RGC
Alert me
Regencell Bioscience Holdings Limited (RGC) EBITDA
Regencell Bioscience Holdings Limited's EBITDA for fiscal 2026 was −$11.6M, compared with −$3.7M in fiscal 2025. Over the past ten years it has ranged from −$11.6M (fiscal 2026) to −$391.0K (fiscal 2019) — the current reading is the lowest in ten years. Regencell Bioscience Holdings Limited ranks 56th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | −$11.6M | — |
| FY2025 | −$3.7M | — |
| FY2024 | −$4.4M | — |
| FY2023 | −$6.0M | — |
| FY2022 | −$7.5M | — |
| FY2021 | −$1.4M | — |
| FY2020 | −$802.9K | — |
| FY2019 | −$391.0K | — |
Against its own ten years
Low −$11.6M
High −$391.0K
Ten-year median
−$4.1M
Current reading's percentile
13
EBITDA against peers
| Company | EBITDA |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | $330.9M |
| XERS Xeris Biopharma Holdings, Inc. compare | $52.9M |
| RGC Regencell Bioscience Holdings Limited | −$12.5M |
| ALVO Alvotech compare | −$84.5M |
| TRLV Trulieve Cannabis Corp. compare | −$104.9M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$165.9M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$313.5M |
| PRGO Perrigo Company plc compare | −$1.2B |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$3.3B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item